Marketresearchnews

Saturday, 22 May 2021

CBCT Dental Imaging Market to Witness Widespread Expansion During 2020-2027

The Global CBCT Dental Imaging Market is expected to register a CAGR of 9.8%and is anticipated to reach USD 817.5 Million by 2023. Dental Cone Beam Computed Tomography (CBCT) is a distinctive type of x-ray machine used in circumstances where regular dental or facial x-rays are not enough. This type of computed tomography scanner uses a special type of technology to produce three dimensional (3D) images of oral structures, soft tissues, nerve paths and bone in the craniofacial region in a single scan.

The growing use of CBCT in orthodontic diagnosis and treatment, increasing the use of CBCT imaging in cosmetic dentistry treatments, and rising adoption of CBCT by the healthcare professionals are the major drivers propelling market growth. However, the lack of awareness for the use of advanced technologies and risk of ionizing radiations for children and teens may hinder the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2203

Key Players

The prominent players in the global CBCT dental imaging market share are Carestream Health (US), Dentsply Sirona (US), FONA Dental, SRO (Slovakia), Gendex (US), Imaging Sciences International, LLC (US), J.MORITA MFG. CORP. (Japan), KaVo Dental GmbH (Germany), New Tom (Italy), Planmeca OY (Finland), Prexion (US), Sinclair Dental/Dentaire (Canada), SOREDEX (Finland), and Vatech Networks (South Korea)

Some of the key strategies followed by the players operating in the global CBCT dental imaging market were innovation, product development, acquisition, and expansion.

Market Dynamics

Many institutes are using CBCT imaging technology is coupled with 3D clinical photography and accurate predictive altering for the precise diagnosis, planning, and treatment of orthodontics, and facial deformities and dental and facial implant surgeries. Institutes such as Inland Institute Oral & Maxillofacial Surgery are using full-craniofacial cone-beam CT (computed tomography) technology for highly accurate 3D radiographic images which will help in diagnosing, and planning and treating oral and maxillofacial surgery. The increasing use of CBCT for oral and maxillofacial surgery is driving the market for global CBCT dental imaging market. Additionally, increasing the use of CBCT in orthodontic diagnosis and treatment and increasing adoption of CBCT by healthcare professionals is likely to support market growth. On the other hand, lack of awareness for the use of advanced technologies and risk of ionizing radiations for children and teens are anticipated to hamper the market growth.

Segmentation

The global CBCT dental imaging market has been segmented into type of detector, application, and end user. Based on detectors, the dental CBCT imaging market has been classified as flat panel detectors and image intensifiers. The global CBCT dental imaging market, by application, has been ranked as dental implants, orthodontics, endodontic, and others. By end user, the market has been categorized as hospitals and dental clinics, academic and research institutes, and others. The hospitals and dental clinics segment accounted for a market value of USD 262 million in 2015.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cbct-dental-imaging-market-2203

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Carotid Artery Disease Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

The Global upcoming Carotid Artery Disease Market trends is expected to register a CAGR of 4.1% to reach USD 11,621.6 million till 2023.

Market Dynamics

Carotid artery disease is a condition in which plaques are developed in the arteries that supply blood to the brain, which often lead to strokes. The prominent factors that drive the market growth are increasing geriatric population, increasing adoption of an unhealthy lifestyle, and the popularity of over-the-counter (OTD) drugs. However, the high cost of diagnostics and surgeries and stringent government regulations for the carotid artery disease are likely to restrain market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6301

Carotid arteries are blood vessels in the neck that supply oxygen-rich blood to the brain. These vessels could get blocked by plaque, a fatty substance consisting of cholesterol, calcium, and other materials. Medication helps to reduce plaque build-up in carotid arteries and blood vessels throughout the body. Ardent efforts by manufacturers of therapeutic drugs for the treatment of carotid artery disease have aided the growth of the global carotid artery disease market. Medications often prescribed for carotid artery disease are antiplatelet medications, anticoagulant medications, tissue plasminogen activator (tPA). The most commonly used anti-platelet medication is aspirin. Other drugs include clopidogrel (Plavix) and dipyridamole (Persantine), which may be prescribed alone or in combination with aspirin to reduce the risk of stroke. This factor is expected to lead to the growth of the global carotid artery disease market and may even increase the revenue-generation ability of market players. The current first line of treatment for carotid artery disease includes anti-platelets medication and tissue plasminogen activator (tPA). The increasing demand for over-the-counter drugs by the patient population is boosting the growth of the market.

Segmentation

The global carotid artery disease market, diagnosis & treatment, has been segmented into diagnosis and treatment. Based on treatment, the market has been further divided into medications and surgical procedures. The medications segment has been sub-segmented into cholesterol-lowering statins, antiplatelet drugs, antihypertensive drugs. The surgical procedures segment has been further divided into carotid endarterectomy, carotid artery angioplasty & stenting, and carotid artery bypass.

Based on end user, the carotid artery disease market has been categorized as hospital & clinics, ambulatory surgical centers, pharmacies, and others.

Regional Analysis

The global carotid artery disease market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest share in the global carotid artery disease market owing to the rising prevalence of chronic diseases, increasing levels of certain fats and cholesterol in the blood, and stringency of government regulations for drug development. According to the 2014 Surgeon General’s Report on smoking and health, it was estimated that 4,00,000 patients aged 70 years and older in the US suffered from asymptomatic carotid artery stenosis.

The European market was the second largest in 2017 in terms of market share. Factors such as growth in the biopharmaceutical sector, increasing government funding to promote research for the prevention of chronic diseases, the presence of developed economies, high per capita disposable incomes, and increased healthcare spending by consumers are driving the growth of the market in this region. According to the World Diabetes Foundation Organization, the number of people estimated to be suffering from diabetes in 2015 was 59.8 million. The increasing cases of diabetes are likely to drive the carotid artery disease market.

In 2017, Asia-Pacific was the third-largest in the global carotid artery disease market owing to a large number of research organizations, low manufacturing and labor cost, development of new infrastructure to support the healthcare industry, and increasing investments by major players. According to the India Brand Equity Foundation, India is becoming a leader in clinical trials, and contract research and manufacturing activities as the cost of drug production in the country are ~33% lower than that of the US. All these factors are likely to contribute to the fastest growth of the Asia-Pacific region during the forecast period.

Key Players

The prominent players in the global carotid artery disease market are W. L. Gore & Associates, Inc., Becton, Dickinson and Company, Terumo Corporation, Hitachi, Ltd, Silk Road Medical, Inc., Abbott, Medtronic, Stryker Corporation, Cardinal Health, and Boston Scientific Corporation.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Drug of Abuse Testing Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Electronic Trial Master File (eTMF) Systems Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

Global eTMF Systems Market is expected to reach a value of USD 1825 Million by 2025, at a CAGR of 13.11% during the assessment period of 2019 to 2025.

The pharmaceutical, as well as the biotechnology companies, face a major challenge to maintain a central repository for the storage of clinical trial documents for use in regulatory submissions. Therefore, there emerges a need to store all the data produced by these companies effectively. As a result, software companies have developed electronic trial master file systems that aid these companies as well as the contract research organizations in systemized storage of files. Moreover, in comparison to the traditional storage systems, electronic trial master file systems facilitate content classification and easier interoperability in clinical trial operations. Therefore, the major companies are continuously involved in new product launches to gain a competitive edge over the other players.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8772

The growth of the global eTMF systems market is fueled by several factors such as rising activities in terms of acquisitions, new solution and service deployments, and collaborations by key players operating in the market, coupled with the increasing number of clinical trial studies. For instance, in October 2019, SureClinical Inc. launched a transparent eTMF pricing policy. To provide value to the prospective users, the company has posted its prices and terms online to battle price discrimination in this industry. However, budget constraints of the small and medium-sized enterprises, along with the dearth of skilled professionals for operating the electronic systems, can hinder the preference of such solutions. As a result, such elements can hamper the growth of the market during the forecast period.

Several market players currently dominate the global eTMF systems market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Phlexglobal, a UK-based specialist provider of TMF and eTMF management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. Such strategies push the growth of the eTMF systems market.

Key Players

Some of the Global Electronic Trial Master File (eTMF) Systems Market Key Players are Aurea, Inc. (US), Covance Inc. (US), ePharmaSolutions (US), MasterControl, Inc. (US), Oracle (US), Phlexglobal (UK), SureClinical Inc. (US), TransPerfect (US), Veeva Systems (US), and Wingspan (IQVIA) (US).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in the base year 2018, owing to the presence of established key players in countries such as the US and Canada. The eTMF systems market in the Americas has been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European eTMF systems market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The eTMF systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The eTMF systems market in this region is anticipated to be the fastest-growing during the assessment period due to the increased adoption rate of eTMF software and services in the Asian countries. The eTMF systems market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global eTMF Systems Market has been segmented based on Component, Deployment Mode, and End User.

The global eTMF systems market has been segmented, based on the component, into software and services. The software segment is expected to hold the majority share of the market owing to the increasing number of solution launches by the prominent players in recent years. The services segment is expected to be the fastest-growing due to the increasing uptake of eTMF services by pharmaceutical and life science companies.

The global eTMF systems market, based on deployment model, has been segmented into cloud/web-based, and on-premise. The cloud/web-based segment holds the maximum share owing to the technological advancements in cloud-based solutions in recent years.

The end-users of the market are pharmaceutical and biotechnology companies, contract research organizations, and others. The increasing number of clinical trials conducted by pharma firms is leading to the market size of the pharmaceutical and biotechnology companies’ segment.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/etmf-systems-market-8772

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Avian Influenza Vaccine Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Global Avian Influenza Vaccine Industry is expected to register a CAGR of 7.25% to reach USD 735.22 Million by 2025. Avian influenza, also known as bird flu, is a viral infection that spreads from bird to bird and can infect other animals or humans also. There are different strains of avian influenza, causing the infection, but H5V1 is the most common virus strain affecting poultry animals.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8769

Market Dynamics

The increasing strategic agreements are expected to drive market growth during the study period. For instance, in February 2018, the NC State College of Veterinary Medicine and Ceva Santé Animale, an animal health company, based in France, collaborated on a distance learning project providing certification in poultry health management for veterinarians in Latin America. Moreover, the increasing public & private initiatives by the government as well as non-government organizations for research & development are also anticipated to drive the market growth.

Segmentation

The Global Avian Influenza Vaccine Market has been segmented by strain and application. The market, based on strain, has been bifurcated into H5, H7, and H9. Based on application, the avian influenza vaccine market has been chicken, turkey, and goose & duck.

Regional Analysis

The Global Avian Influenza Vaccine Market, based on region, has been divided into the APAC & Middle East, Europe, Americas, and Africa.

The APAC & Middle East is likely to dominate the global avian influenza vaccine market. This can be attributed to the increasing production of poultry birds and the rise in avian influenza outbreaks in the region. According to a recent report from the Foreign Agricultural Service/USDA, China recorded 13,800 thousand metric tons of chicken meat production in 2019. Furthermore, various government initiatives for rapid and effective response efforts to emergent zoonotic influenza viruses are also expected to drive market growth.

The European market for the avian influenza vaccine is estimated to be the second-largest during the review period. The growing dependence on poultry as the key source of protein in the diet in this region is expected to boost the growth of the regional market. According to the European Commission, the European Union (EU) produced 15.2 million tons of poultry meat in 2018. Additionally, increasing the production of veterinary products and improved animal husbandry practices in Germany and Poland are further fueling market growth.

Americas is estimated to demonstrate significant market growth owing to the growing meat & poultry industry, the increasing expenditure on animal health, and the presence of a large number of veterinary hospitals in the region. According to the North American Meat Institute, the US exported 3.7 million metric tons (MT) of poultry and poultry variety meats in 2017. The value was estimated at USD 4.5 billion. Moreover, growing government support for creating awareness on avian influenza viruses and improving efficiency for the avian influenza vaccine is also positively affecting the market growth.

Key Players

The Prominent Players in the Global Avian Influenza Vaccine Market are Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico), JOVAC (Jordan), and QYH BIOTECH COMPANY LIMITED (China). Some of the key strategies followed by players operating in the global avian influenza vaccine market were collaborations, acquisition, product approval & launch, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/avian-influenza-vaccine-market-8769

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Friday, 21 May 2021

Interventional Cardiology Market Foraying into Emerging Economies 2020-2027

Global Interventional Cardiology Market size held a value of USD 15,130.75 Million in 2018 and is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.

Interventional cardiology deals with the catheter-based treatment of heart diseases. Scrutinizing all the global territories, it has been noticed that there is a huge rise in the number of cardiac diseases. This can be attributed to the change in lifestyle, leading to lifestyle diseases. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8735

Many market players are dominating the global interventional cardiology market. The prominent players are involved in strategic agreements, product launches, and joint ventures to brace their market positions. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimate Tensei drug-eluting stent in Europe.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held maximum share in the base year 2018, owing to the high incidence rates of cardiac disorders and strategic activities by major players in countries such as the US. The interventional cardiology market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European interventional cardiology market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for interventional cardiology is expected to hold a substantial share owing to the increase in the number of cardiac disorder cases. For instance, in 2016, there were 66,076 deaths due to coronary heart diseases in the UK, which was the third-highest cause of death in that particular year. The interventional cardiology market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The interventional cardiology market in this region is anticipated to be the fastest-growing during the forecast period due to the increasing uptake and adoption rate of newer treatment options by patients as well as medical professionals. The increasing patient pool and mortality rate due to cardiac diseases in these countries also fuel the market growth. For instance, in 2017, ischemic heart disease was the second-highest cause for death in Japan. The interventional cardiology market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Interventional Cardiology Market has been segmented based on Type, and End User.

The market, based on type, has been segmented into stents, percutaneous transluminal coronary angioplasty (PTCA) catheters, plaque modification devices, coronary guidewires, and accessories. The market, based on stents, has been further divided into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. The stents segment held a major share in 2018 owing to the increased number of product launches by key players in the current years. This segment is also expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of coronary artery disease, and continued innovations by players. The market, based on PTCA catheters, has been segmented into balloon catheters, and guiding catheters.

The Global Interventional Cardiology Market has been segmented, based on end-user, into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and others. In 2018, the hospital’s segment held the majority share of the market owing to the increasing number of patient admissions due to coronary diseases. The cardiac catheterization laboratory segment is projected to be the fastest-growing segment owing to the increasing preference of cath labs by medical professionals.

Key Players

Some of the Key Players in the Global Interventional Cardiology Market are ABIOMED (US), Abbott (US), ACIST Medical Systems, Inc. (the US), B. Braun Melsungen AG (Germany), BD (US), Biosense Webster, Inc (US), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (US), Cardinal Health (US), Cook Medical (US), Edwards Lifesciences Corporation (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Life Vascular Devices Biotech S.L. (Spain), Medtronic (Ireland), Merit Medical Systems, Inc (US), Terumo Corporation (Japan), and W. L. Gore & Associates, Inc. (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Influenza Vaccines Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Upcoming Global Influenza Vaccines Market trends expected to register a CAGR of 6.53% to reach USD 7,828.3 Million by 2025. Influenza viruses are one of the major infectious disease threats to the human population. Vaccination is the major public health measure for the prevention of influenza virus infection. Influenza vaccines are also known as flu shots or flu jabs. Currently available seasonal influenza vaccines are either trivalent or quadrivalent in composition.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1621

Market Dynamics

Influenza is an infection of the upper airway caused by an influenza virus, which is commonly known as flu. The most common symptoms include high fever, sore throat, headache, coughing, and sneezing. In 2018, 69,007 people were diagnosed with influenza viruses, out of which 67,733 were diagnosed with the influenza A virus and 1,274 with the influenza B virus, respectively. Moreover, influenza has resulted in between 9.3 million to 49.0 million cases of illnesses since 2010 in the US alone. This surge in influenza epidemics raises the demand for influenza vaccines, thereby contributing to the growth of the global influenza vaccines market. Moreover, increasing public & private initiatives for research & development of influenza vaccine, growing awareness about influenza vaccines, and increasing product launches & approvals

Segmentation

The Global Influenza Vaccines Market has been segmented by influenza Type, Manufacturing Technology, Vaccine Type, and End User.

The market, based on influenza type, has been bifurcated into seasonal and zoonotic. Based on manufacturing technology, the global influenza vaccines market has been bifurcated into egg-based, cell culture-based, and recombinant-based. On the basis of vaccine type, the global influenza vaccines market has been bifurcated into trivalent vaccines and quadrivalent vaccines. Based on end user, the global influenza vaccines market has been classified as hospitals and clinics, research organizations and academic institutions, and others.

Regional Analysis

The Global Influenza Vaccines Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to dominate the global influenza vaccines market. This can be attributed to the rising prevalence of influenza in the region. Each year on average, 5% to 20% of the US population suffers from influenza. Furthermore, there are approximately 31.4 million outpatient visits due to influenza and more than 200,000 hospitalizations each year. This surge in influenza would support market growth in the American region.

The European market for influenza vaccines is expected to be the second largest during the review period. The high prevalence of seasonal influenza and the rise in product launches by key players is expected to boost the growth of the regional market. Moreover, the influenza vaccine uptake has increased to 72% from 2018 to 2019, from 70.5% from 2016 to 2017. This rising demand for influenza vaccines is anticipated to drive the market growth in this region.

The market in Asia-Pacific is expected to register a significant growth rate during the forecast period owing to the rising investment by major companies to enhance their foothold in the regional market. For instance, in April 2017, Serum Institute of India Pvt Ltd acquired the Czech arm of the US-based, firm Nanotherapeutics for about USD 78 million (EUR 72 million) as a part of its growth strategy.

The market in the Middle East & Africa is likely to exhibit the lowest growth owing to the limited access and availability of treatment facilities. The developing healthcare infrastructure, and continuously increasing demand for vaccination are factors expected to drive the growth of the market in the region.

Key Players

The Prominent Players in the Global Influenza Vaccines Market are AstraZeneca (UK), GlaxoSmithKline PLC (UK), Sanofi (France), Abbott Laboratories (US), Seqirus (UK), Hualan Biological Engineering Inc. (China), Mitsubishi Tanabe Pharma (Japan), Serum Institute of India Pvt. Ltd (India), and Mylan NV (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/influenza-vaccination-market-1621

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com